Goldline Pharmaceutical’s SME IPO Oversubscribed by Over 200 Times on Final Day, Boasting a GMP Exceeding 50%
The Goldline Pharmaceutical IPO has emerged as one of the most heavily subscribed SME issues for May, collecting a remarkable subscription rate of 302.94 times by midday on May 14, driven by strong interest from both retail and HNI investors. The IPO, with a total offer size of Rs 11.61 crore, opened on May 12 with a price band set between Rs 41 and Rs 43 per share. As the bidding period concluded on May 14, the allotment is scheduled for May 15, with the shares expected to list on the BSE SME platform on May 19, 2026.
In the grey market, sentiment surrounding Goldline Pharmaceutical appears robust, with a current grey market premium (GMP) of Rs 25, indicating an expected listing price of approximately Rs 68—a 58% increase over the upper price band of Rs 43. The GMP has shown steady gains from Rs 8 at the start of the subscription period to its present level, which reflects a confident outlook among investors, despite broader market volatility experienced earlier this week. The subscription momentum also illustrates increasing demand, particularly from retail and non-institutional investors, with retail bids at 393.28 times and non-institutional at an impressive 438.99 times as of the last update.
This IPO presents a unique opportunity for Indian investors, particularly within the SME segment, which typically offers high growth potential. However, the large lot size of 3,000 shares—requiring a minimum investment of Rs 2.58 lakh for retail applicants—poses a barrier to entry, making allocation a lottery-like affair, especially given the oversubscription rates. Additionally, investors should remain cautious of Goldline’s asset-light business model, which may present supply chain risks, and pending tax proceedings that could impact its operational landscape. Overall, the IPO signifies a promising entry for bullish investors looking to participate in a growing yet volatile sector.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova IPO team.)